Journal of Clinical Pediatrics >
Sporadic MYH9 related diseases in children: a case report
Received date: 2021-07-14
Online published: 2022-08-09
Nonmuscle myosin heavy chain 9 related diseases (MYH9-RD) are part of the causes of hereditary thrombocytopenia, and are often accompanied by renal injury, sensorineural deafness, cataract and other manifestations other than blood system. The patient was a 13-year-old girl with thrombocytopenia for more than 12 years and hematuria and proteinuria for more than 4 years. Peripheral blood smear microscopy showed a decrease in platelet count [(10-30)×109/L] and an increase in platelet volume. Urine routine examination showed protein (+++) and erythrocyte (15-17/HP). The 24-hour urine protein quantification was 4.34 g [equivalent to 76 mg/(kg·d)]. Pure tone threshold measurement suggested high-frequency hearing impairment, and ophthalmic examination showed early-onset cataract. Genetic testing confirmed that the child had a heterozygous variation at c.2104c > t (p.r702c) of MYH9 gene, which was a reported pathogenic variation. Pedigree verification indicated that both parents and elder brother were wild type. MYH9-RD was subsequently diagnosed. Although the child was treated with valsartan and cyclosporine successively, renal damage continued to progress and entered to CKD2 stage. Cataract and hearing impairment were also worsened. For children with refractory thrombocytopenia, it is necessary to be alerted to the possibility of MYH9-RD, and genetic testing is helpful for early diagnosis.
Lining ZHANG , Lei SUN , Xinyu KUANG , Ping WANG , Yulin KANG , Ying WU , Wenyan HUANG . Sporadic MYH9 related diseases in children: a case report[J]. Journal of Clinical Pediatrics, 2022 , 40(8) : 623 -626 . DOI: 10.12372/jcp.2022.21e1061
[1] | Pecci A, Ma X, Savoia A, et al. MYH9: structure, functions and role of non-muscle myosin IIA in human disease[J]. Gene, 2018, 664: 152-167. |
[2] | Fernandez PR, Carriazo JSM, Torra R, et al. MYH9-related disease: it does exist, may be more frequent than you think and requires specific therapy[J]. Clin Kidney J, 2019, 12(4): 488-493. |
[3] | Savoia A, Pecci A. MYH9-related disease[M]. Seattle (WA): University of Washington, Seattle, 2008. |
[4] | David JR, Chun Y, Latimer M, er al. Diagnosis and treatment of MYH9-RD in an Australasian cohort with thrombocytopenia[J]. Platelets, 2018, 29(8): 793-800. |
[5] | Bury L, Megy K, Stephens JC, et al. Next-generation sequencing for the diagnosis of MYH9-RD: predicting pathogenic variants[J]. Hum Mutat, 2020, 41(1): 277-290. |
[6] | Kunishima S, Yusuke O, Muramatsu H, et al. Efficacy of neutrophil non-muscle myosin heavy chain-IIA immunofluorescence analysis in determining the pathogenicity of MYH9 variants[J]. Ann Hematol, 2017, 96(6): 1065-1066. |
[7] | Pecci A, Klersy C, Gresele P, et al. MYH9-related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations[J]. Hum Mutat, 2014, 35(2): 236-247. |
[8] | Zaninetti C, Barozzi S, Bozzi V, et al. Eltrombopag in preparation for surgery in patients with severe MYH9-related thrombocytopenia[J]. Am J Hematol, 2019, 94: E199-E201. |
[9] | Cunha MFMD, Sevignani G, Pavanelli GM, et al. Rare inherited kidney diseases: an evolving field in nephrology[J]. J Bras Nefrol, 2020, 42(2): 219-230. |
/
〈 |
|
〉 |